Does the media prefer SRRK or ROIV?

In the previous week, Scholar Rock had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 9 mentions for Scholar Rock and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.70 beat Scholar Rock's score of 0.02 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BNTX or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Scholar Rock N/A -163.52% -96.67%

Does the media refer more to BNTX or SRRK?

In the previous week, Scholar Rock had 3 more articles in the media than BioNTech. MarketBeat recorded 9 mentions for Scholar Rock and 6 mentions for BioNTech. BioNTech's average media sentiment score of 1.06 beat Scholar Rock's score of 0.02 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 3 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SRRK or INSM more profitable?

Scholar Rock has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Insmed -144.44% -130.11% -51.57%

Does the media favor SRRK or INSM?

In the previous week, Insmed had 4 more articles in the media than Scholar Rock. MarketBeat recorded 13 mentions for Insmed and 9 mentions for Scholar Rock. Insmed's average media sentiment score of 0.94 beat Scholar Rock's score of 0.02 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRRK or VTRS more profitable?

Scholar Rock has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Viatris -2.04% 19.04% 7.62%

Does the media refer more to SRRK or VTRS?

In the previous week, Scholar Rock had 6 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Scholar Rock and 3 mentions for Viatris. Viatris' average media sentiment score of 1.10 beat Scholar Rock's score of 0.02 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GMAB or SRRK more profitable?

Genmab A/S has a net margin of 21.05% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 21.05% 15.34% 8.94% Scholar Rock N/A -163.52% -96.67%

Does the media refer more to GMAB or SRRK?

In the previous week, Scholar Rock had 4 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Scholar Rock and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.16 beat Scholar Rock's score of 0.02 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 3 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Scholar Rock (SRRK) Competitors

$54.70 -2.01 (-3.54%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$54.69 -0.01 (-0.02%)

As of 07/13/2026 06:40 PM Eastern

Compare

SRRK vs. ROIV, BNTX, INSM, VTRS, and GMAB

Should you buy Scholar Rock stock or one of its competitors? MarketBeat compares Scholar Rock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scholar Rock include Roivant Sciences (ROIV), BioNTech (BNTX), Insmed (INSM), Viatris (VTRS), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry.

How does Scholar Rock compare to Roivant Sciences?

Scholar Rock (NASDAQ:SRRK) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Scholar Rock currently has a consensus target price of $56.00, indicating a potential upside of 2.38%. Roivant Sciences has a consensus target price of $33.59, indicating a potential downside of 2.66%. Given Scholar Rock's stronger consensus rating and higher possible upside, equities research analysts plainly believe Scholar Rock is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Scholar Rock had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 9 mentions for Scholar Rock and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.70 beat Scholar Rock's score of 0.02 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Roivant Sciences has higher revenue and earnings than Scholar Rock. Roivant Sciences is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A

Scholar Rock has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Scholar Rock and Roivant Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Scholar Rock has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.02	-$1.29B	-$5.88	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

15.5% of BioNTech shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Scholar Rock has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Scholar Rock	N/A	-163.52%	-96.67%

BioNTech currently has a consensus target price of $129.13, suggesting a potential upside of 43.36%. Scholar Rock has a consensus target price of $56.00, suggesting a potential upside of 2.38%. Given BioNTech's higher probable upside, equities analysts clearly believe BioNTech is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

In the previous week, Scholar Rock had 3 more articles in the media than BioNTech. MarketBeat recorded 9 mentions for Scholar Rock and 6 mentions for BioNTech. BioNTech's average media sentiment score of 1.06 beat Scholar Rock's score of 0.02 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	3 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioNTech and Scholar Rock tied by winning 8 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Insmed?

Scholar Rock (NASDAQ:SRRK) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Scholar Rock has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Insmed	-144.44%	-130.11%	-51.57%

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Scholar Rock presently has a consensus target price of $56.00, suggesting a potential upside of 2.38%. Insmed has a consensus target price of $211.00, suggesting a potential upside of 93.33%. Given Insmed's higher probable upside, analysts plainly believe Insmed is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Scholar Rock has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Scholar Rock has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Insmed	$606.42M	39.01	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 4 more articles in the media than Scholar Rock. MarketBeat recorded 13 mentions for Insmed and 9 mentions for Scholar Rock. Insmed's average media sentiment score of 0.94 beat Scholar Rock's score of 0.02 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Scholar Rock and Insmed tied by winning 8 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Viatris?

Scholar Rock (NASDAQ:SRRK) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Scholar Rock has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Viatris	$14.30B	1.33	-$3.51B	-$0.26	N/A

Scholar Rock presently has a consensus price target of $56.00, suggesting a potential upside of 2.38%. Viatris has a consensus price target of $17.50, suggesting a potential upside of 6.77%. Given Viatris' higher probable upside, analysts clearly believe Viatris is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Scholar Rock has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Viatris	-2.04%	19.04%	7.62%

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

In the previous week, Scholar Rock had 6 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Scholar Rock and 3 mentions for Viatris. Viatris' average media sentiment score of 1.10 beat Scholar Rock's score of 0.02 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Scholar Rock beats Viatris on 9 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, Scholar Rock had 4 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Scholar Rock and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.16 beat Scholar Rock's score of 0.02 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	3 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 10.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Genmab A/S presently has a consensus price target of $38.21, indicating a potential upside of 32.69%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 2.38%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Genmab A/S has a net margin of 21.05% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Scholar Rock	N/A	-163.52%	-96.67%

Genmab A/S has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.83	$963M	$1.32	21.82
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Summary

Genmab A/S beats Scholar Rock on 10 of the 16 factors compared between the two stocks.

Get Scholar Rock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRRK vs. The Competition

Export

Metric	Scholar Rock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.80B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-15.24	20.85	27.13	24.26
Price / Sales	N/A	314.01	589.11	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	22.70	8.49	10.77	6.29
Net Income	-$377.94M	$23.83M	$3.58B	$330.66M
7 Day Performance	-3.29%	-3.56%	-2.10%	-1.32%
1 Month Performance	23.81%	6.31%	3.29%	-0.64%
1 Year Performance	41.75%	48.30%	26.34%	19.08%

Scholar Rock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRRK Scholar Rock	1.7123 of 5 stars	$54.70 -3.5%	$56.00 +2.4%	+46.1%	$6.80B	N/A	N/A	140	Gap Down
ROIV Roivant Sciences	1.5422 of 5 stars	$35.39 +0.7%	$33.59 -5.1%	+203.8%	$25.27B	$8.26M	N/A	860
BNTX BioNTech	4.5286 of 5 stars	$93.93 -3.7%	$129.56 +37.9%	-20.2%	$24.67B	$3.25B	N/A	7,807	Positive News
INSM Insmed	4.0978 of 5 stars	$111.54 -0.1%	$211.86 +89.9%	+11.2%	$24.19B	$606.42M	N/A	1,664
VTRS Viatris	2.7092 of 5 stars	$16.80 +0.6%	$17.50 +4.2%	+79.7%	$19.45B	$14.30B	N/A	30,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRRK) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scholar Rock (SRRK) Competitors

SRRK vs. ROIV, BNTX, INSM, VTRS, and GMAB

How does Scholar Rock compare to Roivant Sciences?

Summary

How does Scholar Rock compare to BioNTech?

Summary

How does Scholar Rock compare to Insmed?

Summary

How does Scholar Rock compare to Viatris?

Summary

How does Scholar Rock compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scholar Rock (SRRK) Competitors

SRRK vs. ROIV, BNTX, INSM, VTRS, and GMAB

How does Scholar Rock compare to Roivant Sciences?

Do analysts recommend SRRK or ROIV?

Does the media prefer SRRK or ROIV?

Is SRRK or ROIV more profitable?

Which has preferable valuation & earnings, SRRK or ROIV?

Which has more risk & volatility, SRRK or ROIV?

Do institutionals and insiders believe in SRRK or ROIV?

Summary

How does Scholar Rock compare to BioNTech?

Which has more risk and volatility, BNTX or SRRK?

Which has preferable earnings & valuation, BNTX or SRRK?

Do insiders & institutionals have more ownership in BNTX or SRRK?

Is BNTX or SRRK more profitable?

Do analysts prefer BNTX or SRRK?

Does the media refer more to BNTX or SRRK?

Summary

How does Scholar Rock compare to Insmed?

Is SRRK or INSM more profitable?

Do institutionals & insiders hold more shares of SRRK or INSM?

Do analysts prefer SRRK or INSM?

Which has more volatility & risk, SRRK or INSM?

Which has preferable valuation and earnings, SRRK or INSM?

Does the media favor SRRK or INSM?

Summary

How does Scholar Rock compare to Viatris?

Which has higher earnings & valuation, SRRK or VTRS?

Do analysts prefer SRRK or VTRS?

Is SRRK or VTRS more profitable?

Do institutionals and insiders have more ownership in SRRK or VTRS?

Which has more volatility and risk, SRRK or VTRS?

Does the media refer more to SRRK or VTRS?

Summary

How does Scholar Rock compare to Genmab A/S?

Does the media refer more to GMAB or SRRK?

Do institutionals & insiders believe in GMAB or SRRK?

Do analysts recommend GMAB or SRRK?

Is GMAB or SRRK more profitable?

Which has more volatility and risk, GMAB or SRRK?

Which has preferable valuation & earnings, GMAB or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools